
RAS Inhibitor Zoldonrasib Brings Clinical Benefit in Patients with G12D Mutated Non-Small Cell Advanced Lung Cancer
An interview with: Kathryn C Arbour MD, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York USA And: Ryan B Corcoran MD PhD, Massachusetts General Cancer Center, Associate Pr
An interview with: Kathryn C Arbour MD, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York USA
And: Ryan B Corcoran MD PhD, Massachusetts General Cancer Center, Associate Professor of Medicine Harvard Medical School, Co-Chair, American Association for Cancer Research Clinical Trials Committee
CHICAGO, USA— The four per cent of patients with previously treated non-small cell lung cancer whose tumors harbor a KRAS G12D mutation may soon have an effective targeted treatment: currently an unmet need. Clinical benefit from the oral KRAS G12D inhibitor zoldonrasib is reported in findings presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
First author of the research Kathryn C Arbour MD, from Memorial Sloan Kettering Cancer Center in New York, told Audio Journal of Oncology correspondent Peter Goodwin how the drug’s ability to target both active and inactive conformations of the KRAS G12D oncogene could help overcome treatment resistance.
Ryan B Corcoran MD PhD, from the Massachusetts General Cancer Center and Harvard University, Co-Chair of the AACR Clinical Trials Committee, who was not involved with the research, adds his comments on the clinical implications for treating solid tumors harboring the RAS G12D mutation.
AACR 2025 Abstract Title:
“Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors”
Next in AACR 2025
All 14 interviewsInterview 14 of 14

Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab
Audio Journal of Oncology Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-
Related Episodes

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?
SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma
BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca